Decrease of IL-23-induced arthritis in anti-γδ TCR mAb treated mice. (A) Schematic illustration of the experimental protocols. B10.RIII mice at the age of 10–12 weeks were treated on days 0, 5 and 10 with anti-γδ TCR or isotype control mAb prior to GFP or IL-23 MC injection at day 2 (n = 10–13 per group). (B) Serum IL-23 levels by ELISA of each group (n = 4–5 per group). Median, interquartile minimum, and maximum range is depicted by box plots, ****p < 0.0001 by one-way ANOVA with Sidak’s multiple comparisons test. (C) Time course of disease incidence and (D) severity score of arthritis in mice injected with GFP or IL-23 MC and treated with anti-γδ TCR or isotype mAb (n = 10–14 per group). *p < 0.05 by using two-tailed Student’s t-test. Representative pictures showing the hind paws of B10.RIII mice injected with GFP MC (E) or IL-23 MC + isotype (F) or IL-23 MC + anti-γδ TCR (G). (H) Representative H&E stained sections of day-11 metatarsophalangeal joint from GFP MC and IL-23 MC injected mice treated with isotype (middle column) or γδ TCR mAb (right column) are shown (20× objective). The black arrow indicates synovial hyperplasia. Scale bars, 50 μm. Data are representative of three independent experiments. All data are shown as mean ± SEM.